Zobrazeno 1 - 10
of 362
pro vyhledávání: '"Shengxiang, Ren"'
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or
Externí odkaz:
https://doaj.org/article/85de6aafaeee4fa88278b3e70385a7cd
Autor:
Tao Jiang, Jian Chen, Haowei Wang, Fengying Wu, Xiaoxia Chen, Chunxia Su, Haiping Zhang, Fei Zhou, Ying Yang, Jiao Zhang, Huaibo Sun, Henghui Zhang, Caicun Zhou, Shengxiang Ren, Peifang Wei
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 18, Pp 2213-2222 (2024)
Abstract. Background:. Programmed death 1 (PD-1) blockade plus chemotherapy has become the new first-line standard of care for patients with advanced non-small-cell lung cancer (NSCLC). Yet not all NSCLC patients benefit from this regimen. This study
Externí odkaz:
https://doaj.org/article/567b3c802f224a39994c14ab712c6a7f
Autor:
Chuchu Shao, Xinxin Zhi, Shiqi Mao, Leilei Wu, Jia Yu, Shuo Yang, Wanying Wang, Keyi Jia, Libo Luo, Xinyu Liu, Tao Jiang, Fei Zhou, Bin Chen, Lei Wang, Guanghui Gao, Jingyun Shi, Xiaoxia Chen, Fengying Wu, Shengxiang Ren
Publikováno v:
Thoracic Cancer, Vol 15, Iss 10, Pp 778-787 (2024)
Abstract Background The effective therapeutic approach is still an unmet need for patients diagnosed with both lung cancer and interstitial lung disease (ILD). This is primarily due to the possible risk of ILD exacerbation caused by surgery or radiot
Externí odkaz:
https://doaj.org/article/da7002b8558a4abe886832810f433e58
Autor:
Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang, Caicun Zhou
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-20 (2024)
Abstract Background KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenocarcinoma displays
Externí odkaz:
https://doaj.org/article/c7b5672223364226bbaa66549a19fe3f
Autor:
Leilei Wu, Bo Cheng, Xiaojiang Sun, Zhenshan Zhang, Jingjing Kang, Yun Chen, Qinghua Xu, Shuangyan Yang, Yujie Yan, Shengxiang Ren, Caicun Zhou, Yaping Xu
Publikováno v:
MedComm, Vol 5, Iss 3, Pp n/a-n/a (2024)
Abstract This study aimed to evaluate the efficacy and safety of induction immunochemotherapy followed by definitive chemoradiotherapy (CRT) for unresectable locally advanced non‐small cell lung cancer (LA‐NSCLC). We identified unresectable stage
Externí odkaz:
https://doaj.org/article/1108e4ea86cb4177a9898ac66fadcb94
Autor:
Pingli Wang, Liming Cao, Panwen Tian, Shengxiang Ren, Liyun Miao, Chengzhi Zhou, Yun Fan, Yuping Li, Dongqing Lv, Xin Zhao, Mei Yang, Chaonan Zhu, Bing Yu, June Xu, Yong Song, Kai Wang
Publikováno v:
Cancer Communications, Vol 43, Iss 9, Pp 1059-1063 (2023)
Externí odkaz:
https://doaj.org/article/39fceaab02494d4db904bd9cf47c9890
Autor:
Fei Zhou, Jianguo Sun, Lingyun Ye, Tao Jiang, Wei Li, Chunxia Su, Shengxiang Ren, Fengying Wu, Caicun Zhou, Guanghui Gao
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-17 (2023)
Abstract Background Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple cancer types. However, the roles and the underlying mechanism of fibrone
Externí odkaz:
https://doaj.org/article/2c7bcf434f6a4eaa9a7dfe203efef587
Autor:
Shiqi Mao, Shuo Yang, Xinyu Liu, Xingya Li, Qiming Wang, Yiping Zhang, Jianhua Chen, Yan Wang, Guanghui Gao, Fengying Wu, Tao Jiang, Jiao Zhang, Ying Yang, Xiang Lin, Xiaoyu Zhu, Caicun Zhou, Shengxiang Ren
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-10 (2023)
Abstract Background Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate objective response
Externí odkaz:
https://doaj.org/article/881e6699d1604387a9dfe886cec0c786
Autor:
Ying Liu, Jia Fan, Jun Zhao, Tianshu Liu, Caicun Zhou, Shengxiang Ren, Ying Cheng, Caigang Liu, Xicheng Wang, Sheng Hu, Yufeng Cheng, Yueyin Pan, Shegan Gao, Yalun Li, Bao-Hui Han, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Yongzhong Luo, Huijie Duan, Shuni Wang, Xinfeng Yang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus
Externí odkaz:
https://doaj.org/article/e64460bcef6e43cab39d61f9e42164e6
Publikováno v:
Chinese Medical Journal, Vol 136, Iss 4, Pp 379-393 (2023)
Abstract. Monoclonal antibodies have been successfully incorporated into the current therapeutical landscape of lung cancer in the last decades. Recently, with technological advances, bispecific antibodies (bsAbs) have also shown robust efficacy in t
Externí odkaz:
https://doaj.org/article/7cde2dcbd44e4dd99801958cf5b437d6